nach oben

Die Onkologie

Erschienen in:

18.12.2022 | CME

Patientenabgeleitete Tumororganoide – ein Therapiemodell für die Präzisionsonkologie

verfasst von: Linus R. Schömig, M.Sc., Prof. Dr. med. Michael Quante

Erschienen in: Die Onkologie | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Organoide sind stammzellbasierte In-vitro-Zellkulturen, die sich nicht nur durch ihre 3‑dimensionale Struktur, sondern auch durch ihre Multizellularität und ein hohes Maß an Selbstorganisation auszeichnen. Aufgrund ihrer starken Ähnlichkeit zu den Primärgeweben, aus denen sie isoliert wurden, stellen Organoide ein geeignetes Therapiemodell für molekulare und funktionelle Analysen innerhalb der personalisierten Medizin dar. Gerade im Bereich der Präzisionsonkologie, wo patientenspezifische Therapiemodelle dringend benötigt werden, können Organoide das vorhandene Repertoire, bestehend aus 2‑dimensionalen Zellkulturen und Modellen patientenabgeleiteter Xenografts, bereichern.

Hofer M, Lutolf MP (2021) Engineering organoids. Nat Rev Mater 6(5):402–420

Sato T et al (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459(7244):262–265

Li Y et al (2020) Organoid based personalized medicine: from bench to bedside. Cell Regen 9(1):21

Clevers H (2016) Modeling development and disease with organoids. Cell 165(7):1586–1597

Bose S, Clevers H, Shen X (2021) Promises and challenges of organoid-guided precision medicine. Med (N Y) 2(9):1011–1026

Aisenbrey EA, Murphy WL (2020) Synthetic alternatives to matrigel. Nat Rev Mater 5(7):539–551

Kleinman HK, Martin GR (2005) Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 15(5):378–386

Broguiere N et al (2018) Growth of epithelial organoids in a defined hydrogel. Adv Mater 30(43):e1801621

Cruz-Acuna R et al (2017) Synthetic hydrogels for human intestinal organoid generation and colonic wound repair. Nat Cell Biol 19(11):1326–1335

10.

Gjorevski N et al (2016) Designer matrices for intestinal stem cell and organoid culture. Nature 539(7630):560–564

11.

Jabaji Z et al (2014) Type I collagen as an extracellular matrix for the in vitro growth of human small intestinal epithelium. PLoS ONE 9(9):e107814

12.

Lindborg BA et al (2016) Rapid induction of cerebral organoids from human induced pluripotent stem cells using a chemically defined hydrogel and defined cell culture medium. Stem Cells Transl Med 5(7):970–979

13.

Bartfeld S et al (2015) In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 148(1):126–136.e6

14.

van de Wetering M et al (2015) Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161(4):933–945

15.

Boj SF et al (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160(1):324–338

16.

Hu H et al (2018) Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell 175(6):1591–1606.e19

17.

Huch M et al (2015) Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160(1):299–312

18.

Kessler M et al (2015) The notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat Commun 6:8989

19.

Gao D et al (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell 159(1):176–187

20.

Karthaus WR et al (2014) Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159(1):163–175

21.

Saito Y et al (2018) Development of a functional thyroid model based on an organoid culture system. Biochem Biophys Res Commun 497(2):783–789

22.

Schutgens F et al (2019) Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat Biotechnol 37(3):303–313

23.

McCracken KW et al (2014) Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516(7531):400–404

24.

Costa EC et al (2016) 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv 34(8):1427–1441

25.

Langhans SA (2018) Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol 9:6

26.

Imamura Y et al (2015) Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep 33(4):1837–1843

27.

Haisler WL et al (2013) Three-dimensional cell culturing by magnetic levitation. Nat Protoc 8(10):1940–1949

28.

Ravi M et al (2015) 3D cell culture systems: advantages and applications. J Cell Physiol 230(1):16–26

29.

Pontes Soares C et al (2012) 2D and 3D-organized cardiac cells shows differences in cellular morphology, adhesion junctions, presence of myofibrils and protein expression. PLoS ONE 7(5):e38147

30.

Jensen C, Teng Y (2020) Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci 7:33

31.

Toolan HW (1953) Growth of human tumors in cortisone-treated laboratory animals: the possibility of obtaining permanently transplantable human tumors. Cancer Res 13(4):389–394

32.

Byrne AT et al (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 17(4):254–268

33.

Sachs N et al (2018) A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172(1):373–386.e10

34.

Calandrini C et al (2020) An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nat Commun 11(1):1310

35.

Jacob F et al (2020) A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180(1):188–204.e22

36.

Kopper O et al (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25(5):838–849

37.

Drost J et al (2015) Sequential cancer mutations in cultured human intestinal stem cells. Nature 521(7550):43–47

38.

Matano M et al (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 21(3):256–262

39.

Dotti I et al (2017) Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. Gut 66(12):2069–2079

40.

Howell KJ et al (2018) DNA methylation and transcription patterns in intestinal epithelial cells from pediatric patients with inflammatory bowel diseases differentiate disease subtypes and associate with outcome. Gastroenterology 154(3):585–598

41.

Joshi R et al (2020) The DNA methylation landscape of human cancer organoids available at the American type culture collection. Epigenetics 15(11):1167–1177

42.

Driehuis E et al (2019) Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov 9(7):852–871

43.

Ooft SN et al (2019) Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med 11(513):eaay2574. https://doi.org/10.1126/scitranslmed.aay2574CrossRef

44.

Vlachogiannis G et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359(6378):920–926

45.

Hidalgo M et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013

46.

Driehuis E et al (2019) Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A 116(52):26580–26590. https://doi.org/10.1073/pnas.1911273116CrossRef

47.

Li X et al (2018) Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat Commun 9(1):2983

48.

Dijkstra KK et al (2020) Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep 31(5):107588

49.

Heinrich K et al (2022) Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) molecular tumor board. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-022-04165-0CrossRef

50.

Hennig A et al (2022) Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. J Pathol 257(5):607–619

51.

Sohal D et al (2020) SWOG S1505: results of perioperative chemotherapy (peri-op Ctx) with mfolfirinox versus gemcitabine/nab-paclitaxel (gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 38(15):4504–4504

52.

Peschke K et al (2022) Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med 14(4):e14876. https://doi.org/10.15252/emmm.202114876CrossRef

53.

Yao Y et al (2020) Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26(1):17–26.e6

54.

Ganesh K et al (2019) A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med 25(10):1607–1614

55.

Arena S et al (2020) A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin. Clin Cancer Res 26(6):1372–1384

56.

Li J et al (2019) Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening. J Cancer Res Clin Oncol 145(11):2637–2647

57.

Pasch CA et al (2019) Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin Cancer Res 25(17):5376–5387

58.

Steele NG et al (2019) An organoid-based preclinical model of human gastric cancer. Cell Mol Gastroenterol Hepatol 7(1):161–184

59.

Broutier L et al (2017) Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med 23(12):1424–1435

60.

Yan HHN et al (2018) A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell 23(6):882–897.e11

Titel: Patientenabgeleitete Tumororganoide – ein Therapiemodell für die Präzisionsonkologie
verfasst von: Linus R. Schömig, M.Sc.
Prof. Dr. med. Michael Quante
Publikationsdatum: 18.12.2022
Verlag: Springer Medizin
Erschienen in: Die Onkologie / Ausgabe 1/2023
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-022-01268-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Patientenabgeleitete Tumororganoide – ein Therapiemodell für die Präzisionsonkologie

Zusammenfassung

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Wie innovative Techniken die Kopf-Hals-Onkologie verbessern

Integrierter digitaler Operationssaal für die Optimierung der Kopf-Hals-Tumorchirurgie

Implementierung eines Symptom- und Belastungsscreenings bei Kopf-Hals-Tumor-Patient*innen – ein Erfahrungsbericht

Bildgeführte Strahlentherapie in der Kopf-Hals-Onkologie

Innovative Konzepte für die erfolgreiche Behandlung von Kopf-Hals-Tumoren

Panelsequenzierung in der Kopf-Hals-Onkologie am Beispiel von sinunasalen und Speicheldrüsenmalignomen

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie